NDRG1 and hepatocellular carcinoma: To test this hypothesis, we treated Hep3B cells (under normoxia; no NDRG1) with 10 μM of the GSK-3β agonist LY294002, or the Nur77 agonist Cns-A for 48 hours, and then analyzed β-catenin expression and localization in HCC cells.